Filing summary
Entity and period: The supplied filing is Genesis Biopharma, Inc.’s Form 10-K for the fiscal year ended December 31, 2011—not an Iovance Biotherapeutics filing. The company describes itself as a development-stage biotechnology business. Its 2011 results are not directly comparable with prior years because it shifted from anti-CD55 antibody research to developing Contego, an adoptive cell therapy using tumor-infiltrating lymphocytes (TILs).
Business context and outlook
Contego was being developed primarily for Stage IV metastatic melanoma, with possible future investigation in ovarian, breast and colorectal cancers. The company had licensed relevant technology non-exclusively from NIH, entered a five-year research agreement (CRADA) with NIH/NCI, and contracted with Lonza for manufacturing-process development and manufacturing services. The product had not entered company-sponsored clinical trials or received FDA approval.
Management planned to develop a manufacturing process and prepare an IND, targeting submission in late 2013. Subject to FDA clearance, management anticipated a pivotal trial beginning in early 2014 and described an accelerated-approval goal within four years. These were forward-looking plans, dependent on financing, manufacturing progress and regulatory authorization; no assurance was given that they would be achieved.
Financial results and liquidity
| Metric | 2011 | 2010 |
|---|---|---|
| Revenue | $0 | $0 |
| Total costs and expenses | $21.22 million | $0.82 million |
| Net loss | $25.69 million | $1.61 million |
| Net loss per share, basic and diluted | $0.34 | $0.02 |
| Net cash used in operating activities | $6.19 million | $0.62 million |
| Cash and cash equivalents at year-end | $0.51 million | $1.29 million |
| Total assets at year-end | $0.57 million | $1.46 million |
| Stockholders’ equity (deficiency) at year-end | $(12.78) million | $0.64 million |
The filing reports no product revenue and no operating margin. Operating expenses were $19.30 million in 2011, while research and development costs were $1.76 million and impairment of an intangible asset was $0.16 million. The net loss also reflected substantial financing-related and non-cash items, including $5.00 million of convertible-note discount amortization, $1.60 million gain from the change in fair value of derivative liabilities, and extensive stock-based compensation.
At December 31, 2011, current liabilities were $13.35 million, including $5.00 million of convertible notes and $7.94 million of derivative liabilities. Working capital was reported as a $4.89 million deficiency excluding derivative liabilities. The company stated that it had only enough cash for approximately one month of operations and disclosed substantial doubt about its ability to continue as a going concern. It had no bank credit line or committed source of additional funding.
Material changes and unusual items
- Net loss rose to $25.69 million from $1.61 million in 2010; reported quarterly losses were $0.56 million, $10.96 million, $5.82 million and $8.35 million in 2011’s first through fourth quarters, respectively.
- Operating expenses increased sharply as the company hired executives, expanded its board and advisory functions, and incurred professional and development costs. The filing attributes $14.61 million of 2011 operating expenses to non-cash share-based compensation.
- The company discontinued the anti-CD55 program after research failed to meet preclinical development endpoints. It recorded a $0.16 million impairment charge and agreed to terminate the CRT license, return the related rights, and pay CRT approximately $29,000 and Nottingham University approximately $25,000.
- Cash used in operations increased to $6.19 million from $0.62 million. The company raised $5.00 million gross through 7% convertible notes and warrants in July 2011, alongside equity financing; net cash provided by financing activities was $5.49 million.
- The $5.00 million senior unsecured convertible notes were extended several times and were due March 30, 2012. The company said it lacked funds to repay them. Default could raise interest to 15% and allow holders to demand redemption under specified premium-based terms.
- The company was in default on a $250,000 CRADA installment due in March 2012, exposing the agreement to termination. It also disclosed an NIH invoice of $684,183 due May 26, 2012.
Risks, contingencies and controls
- Funding and continuity: Management said it needed substantial near-term financing and estimated that developing Contego could require more than $35 million. The filing also gives a 2012 projected spending range of approximately $25–$30 million for development, scale-up, regulatory and corporate needs; these are different management estimates with differing scopes. No financing commitments were disclosed.
- Development and regulatory: Contego remained early-stage. Clinical success, FDA clearance, accelerated approval, manufacturing scale-up, trial timing and commercial adoption were uncertain. The filing notes that no TIL adoptive cell therapy had been approved for marketing in the United States.
- Third-party dependence and intellectual property: The company relied on NIH/NCI, Lonza and other outside providers. The NIH license was non-exclusive, included a 6% royalty on net sales, and carried potentially substantial milestone payments—up to $6.05 million for melanoma and $36.3 million across four indications if all stated milestones were achieved.
- Convertible financing and dilution: Note and warrant terms included anti-dilution provisions; further equity or convertible financing could materially dilute existing holders. Outstanding options and warrants added potential dilution.
- Internal controls: Management identified two material weaknesses involving financial-reporting resources and closing procedures, and controls over securities issuance and disclosure. Management concluded disclosure controls and internal control over financial reporting were ineffective. The auditor issued an adverse opinion on internal control, while giving an unqualified opinion on the financial statements.
- Market and operations: Shares traded sporadically on the OTC Bulletin Board. The company had only two full-time employees, no laboratory facilities, and no manufacturing capability of its own.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Genesis Biopharma, Inc., not Iovance Biotherapeutics, Inc.
- Verify whether the March 30, 2012 note maturity was repaid, converted, further extended or defaulted, and the resulting obligations.
- Check whether the overdue CRADA payment and NIH invoice were settled and whether the CRADA remained in force.
- Review subsequent cash balances, financing proceeds, dilution, and the company’s ability to fund operations and planned development.
- Verify the status of Contego’s manufacturing work, IND submission, clinical-trial plans and regulatory discussions against subsequent disclosures.
- Track remediation of the disclosed material weaknesses and any later auditor conclusions.